Biomarkers for predicting bladder cancer therapy response DOI

Ioana Maria Mihai,

Gang Wang

Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, Journal Year: 2024, Volume and Issue: 33(3), P. 533 - 547

Published: Dec. 12, 2024

The advent of precision medicine has underscored the importance biomarkers in predicting therapy response for bladder cancer, a malignancy marked by considerable heterogeneity. This review critically examines current landscape to forecast treatment outcomes cancer patients. We explore range biomarkers, including genetic, epigenetic, proteomic, and transcriptomic indicators, from multiple sample sources, urine, tumor tissue blood, assessing their efficacy responses chemotherapy, immunotherapy, targeted therapies. Despite promising developments, translation these into clinical practice faces significant challenges, such as variability biomarker performance, necessity large-scale validation studies, integration testing routine workflows. also highlight need standardized methodologies robust assays ensure consistency reliability. Future directions point towards longitudinal studies development combination panels enhance predictive accuracy. emphasizes transformative potential improving patient advocates continued collaborative efforts overcome existing barriers this rapidly evolving field.

Language: Английский

Urease-Driven Janus Nanomotors for Dynamic Enrichment and Multiplexed Detection of Bladder Cancer MicroRNAs in Urine DOI
Hong Zhou, Qi Liu, Minghui Chen

et al.

ACS Sensors, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 5, 2025

Bladder cancer diagnosis typically involves approaches such as cystoscopy, biopsy, urine cytology, and medical imaging. However, these invasive procedures carry a risk of complications, direct in vitro detection on clinical samples often results low sensitivity. Therefore, this study proposed urease-driven magnetic nanomotors for the simultaneous bladder biomarkers miRNA-21 miRNA-182 samples, aiming noninvasive diagnosis. The nanomotor was constructed from gold nanorods, mesoporous organo-silica, Fe3O4, hairpin DNA (hDNA), functioning recognition probe target miRNAs. In urea solution, urease catalyzed into ammonia carbon dioxide, propelling about 60 min, which enhanced capacity probes to capture Subsequently, enrichment enabled highly sensitive dual-miRNA analysis, allowing quantification with limits 29 362 fM, respectively. nanoprobes also effectively detected miRNAs spiked samples. This multiple increased reliability diagnosis, presenting novel strategy through precise analysis actual

Language: Английский

Citations

0
Circulating tumor DNA: a revolutionary approach for early detection and personalized treatment of bladder cancer DOI Creative Commons
Yan Zhou,

Rongzhong Wang,

Mingtang Zeng

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: March 21, 2025

Bladder cancer is a malignant tumor with high global incidence and recurrence rate. Traditional diagnostic methods, such as cystoscopy urine cytology, have limitations in sensitivity specificity, particularly detecting low-grade bladder cancer. Circulating DNA (ctDNA) offers non-invasive alternative, reflecting genetic characteristics through blood samples. It demonstrates repeatability, making it promising tool for early detection, monitoring, treatment evaluation. Clinical studies shown that ctDNA not only detects burden but also captures dynamic mutations, aiding personalized strategies. Despite its potential, clinical implementation of faces challenges, including optimization detection techniques, standardization, the cost testing. This paper explores role advancing diagnosis treatment, focus on refining application guiding future research toward improved patient outcomes.

Language: Английский

Citations

0
Investigation of the Molecular Mechanisms of Paraoxonase‐2 Mediated Radiotherapy and Chemotherapy Resistance in Oral Squamous Cell Carcinoma DOI Creative Commons
Mehta Vedant Kamal, Krishnananda Prabhu, Krishna Sharan

et al.

Clinical and Translational Science, Journal Year: 2025, Volume and Issue: 18(4)

Published: March 25, 2025

Oral squamous cell carcinoma (OSCC) is a common form of cancer, with 390,000 new cases estimated for 2022. OSCC has poor prognosis, largely due to high recurrence rate and resistance therapy. Cancer cells develop standard therapy owing various factors, such as genetic predispositions, alterations in the apoptotic pathway coupled DNA repair pathways, drug efflux, detoxification. This review aimed at exploring crucial role paraoxonase 2 (PON2) conferring chemotherapy radiotherapy cells. PON2, an antioxidant enzyme, protects cancer from oxidative stress caused by these treatments. By influencing pathways mechanisms, PON2 can reduce effectiveness attempt explore complex molecular mechanisms modulated mitigation stress, enhancement repair, apoptosis regulation, efflux modulation, detoxification, which decrease treatment efficacy.

Language: Английский

Citations

0
Urine-Based Biomarker Test Uromonitor® in the Detection and Disease Monitoring of Non-Muscle-Invasive Bladder Cancer—A Systematic Review and Meta-Analysis of Diagnostic Test Performance DOI Open Access

Anton Kravchuk,

Ingmar Wolff, Christian Gilfrich

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(4), P. 753 - 753

Published: Feb. 11, 2024

Optimal urine-based diagnostic tests (UBDT) minimize unnecessary follow-up cystoscopies in patients with non-muscle-invasive bladder-cancer (NMIBC), while accurately detecting high-grade without false-negative results. Such UBDTs have not been comprehensively described upon a broad, validated dataset, resulting cautious guideline recommendations. Uromonitor®, DNA-assay hotspot alterations TERT, FGFR3, and KRAS, shows promising initial However, systematic review merging all available data is lacking. Studies investigating the performance of Uromonitor® NMIBC until November 2023 were identified PubMed, Embase, Web-of-Science, Cochrane, Scopus, medRxiv databases. Within aggregated analyses, test area under curve/AUC calculated. This project fully implemented PRISMA statement. Four qualifying studies comprised total 1190 urinary (bladder-cancer prevalence: 14.9%). Based on comprehensive sensitivity, specificity, positive-predictive value/PPV, negative-predictive value/NPV, accuracy 80.2%, 96.9%, 82.1%, 96.6%, 94.5%, respectively, an AUC 0.886 (95%-CI: 0.851–0.921). In meta-analysis two comparing cytology, significantly outperformed cytology PPV, accuracy, no significant differences observed for specificity NPV. supports use considering its favorable performance. cohort 1000 prevalence ~15%, this UBDT would avert 825 (true-negatives) missing 30 cases (false-negatives). Due to currently limited from only four heterogeneous quality, confirmatory are needed.

Language: Английский

Citations

3
Hypoxia‐mediated attenuation of EGLN2 inhibition of the NF‐κB signaling pathway leads to the formation of a loop between HIF‐1α and MUC1‐C promoting chemoresistance in bladder cancer DOI

Liangliang Qing,

Qingchao Li, Yongjin Yang

et al.

Molecular Carcinogenesis, Journal Year: 2024, Volume and Issue: 63(7), P. 1303 - 1318

Published: April 18, 2024

The expression pattern of MUC1-C in tumors is closely linked to tumor progression; however, its specific mechanism remains unclear. cancer and adjacent normal tissues was detected using immunohistochemistry Western blot. IC

Language: Английский

Citations

3
A panel of four plasma amino acids is a promising biomarker for newly diagnosed bladder cancer DOI
Zhipeng Liu, Chunying Teng, Wenting Wan

et al.

Clinical Nutrition, Journal Year: 2024, Volume and Issue: 43(7), P. 1599 - 1608

Published: May 17, 2024

Language: Английский

Citations

3
Bladder cancer biomarkers: current approaches and future directions DOI Creative Commons

Melika Ahangar,

Frouzandeh Mahjoubi, Seyed Javad Mowla

et al.

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Nov. 29, 2024

Bladder cancer is a significant health concern worldwide, necessitating effective diagnostic and monitoring strategies. Biomarkers play crucial role in the early detection, prognosis, treatment of this disease. This review explores current landscape bladder biomarkers, including FDA-approved molecular biomarkers emerging ones. such as BTA stat, TRAK, NMP22, have been instrumental diagnosing cancer. These are derived from urinary samples particularly useful due to their sensitivity specificity. As we move forward, should continue seek ways optimize our processes outcomes, these markers remain seriously challenged detection limited For instance, sensitivities stat tumor varied between 40-72%, while its specificities vary 29-96%. In same way, 70% 80% specificity recorded for 11-85.7% 77-100% documented NMP22 BladderChek. The given variations, especially low diagnosis at an stage call invention better systems. Moreover, different sample collection handling procedures applied laboratories further contribute inconsistent results obtained. Extracellular vesicles (EVs) exosomes, which carry vast number proteins, being considered potential biomarkers. Although show promise, challenges non-standardized isolation techniques lack reproducibility across studies. discovery new ongoing. UBC

Language: Английский

Citations

2
Investigating angiogenin/ribonuclease 5 as a diagnostic biomarker for bladder cancer: In-depth analysis from a systematic review and meta-analysis DOI
Amir Hossein Aalami, Hossein Abdeahad, Farnoosh Aalami

et al.

Clinical Biochemistry, Journal Year: 2024, Volume and Issue: 130, P. 110780 - 110780

Published: June 19, 2024

Language: Английский

Citations

2
TC-Sniffer: A Transformer-CNN Bibranch Framework Leveraging Auxiliary VOCs for Few-Shot UBC Diagnosis via Electronic Noses DOI
Yingying Jian, Nan Zhang,

Yunzhe Bi

et al.

ACS Sensors, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 13, 2024

Utilizing electronic noses (e-noses) with pattern recognition algorithms offers a promising noninvasive method for the early detection of urinary bladder cancer (UBC). However, limited clinical samples often hinder existing artificial intelligence (AI)-assisted diagnosis. This paper proposes TC-Sniffer, novel bibranch framework few-shot UBC diagnosis, leveraging easily obtainable UBC-related volatile organic components (VOCs) as auxiliary classification categories. These VOCs are biomarkers UBC, helping model learn more UBC-specific features, reducing overfitting in small sample scenarios, and reflecting imbalanced distribution samples. TC-Sniffer employs intensity-based augmentation to address size issues focal loss alleviate bias due class imbalance caused by VOCs. The architecture combines transformers temporal convolutional neural networks capture long- short-range dependencies, achieving comprehensive representation learning. Additionally, feature-level constraints further enhance learning distinctive features each class. Experimental results using e-nose data collected from custom-designed sensor array show that significantly surpasses approaches, mean accuracy 92.95% only five training Moreover, fine-grained can distinguish between nonmuscle-invasive (NMIBC) muscle-invasive (MIBC), both which subtypes UBC. superior performance highlights its potential timely accurate diagnosis challenging settings.

Language: Английский

Citations

2
Applications of Biosensors in Bladder Cancer DOI
Kun Cheng, Shun Wan,

Jian-Wei Yang

et al.

Critical Reviews in Analytical Chemistry, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 20

Published: July 8, 2024

Bladder cancer (BC) is the tenth most common globally, predominantly affecting men. Early detection and treatment are crucial due to high recurrence rates poor prognosis for advanced stages. Traditional diagnostic methods like cystoscopy imaging have limitations, leading exploration of noninvasive such as liquid biopsy. This review highlights application biosensors in BC, including electrochemical optical sensors detecting tumor markers proteins, nucleic acids, other biomolecules, noting their clinical relevance. Emerging therapeutic approaches, antibody-drug conjugates, targeted therapy, immunotherapy, gene also explored, role corresponding biomarkers guide these treatments examined. Finally, addresses current challenges future directions biosensor applications highlighting need large-scale trials integration technologies deep learning enhance accuracy efficacy.

Language: Английский

Citations

1